Drug intelligence / Profile preview

diacetoxyscirpenol

Development stage
Discontinued
Modality
Small Molecules
Administration
Oral, Dermal, Inhalation, Parenteral
01

Overview

Diacetoxyscirpenol is a **type A trichothecene mycotoxin**, primarily produced by *Fusarium* fungi, and is part of a group of potent cytotoxins structurally characterized by a tricyclic sesquiterpenoid epoxide[1][5][6]. Trichothecene mycotoxins, including diacetoxyscirpenol, act as **potent inhibitors of protein synthesis**: they cross the plasma membrane and bind to ribosomes, disrupting the active site of peptidyl transferase in the large 28S ribosomal RNA[1][6]. This blocks the initiation, elongation, and termination phases of protein synthesis, leading to cell cycle disruption, apoptosis, ribotoxic stress responses, inhibition of DNA and RNA synthesis, and heightened oxidative stress[1][6]. As a result, diacetoxyscirpenol is cytotoxic to most eukaryotic cells, particularly those that are rapidly dividing, and has been studied as both an immunosuppressant and a potential anticancer agent (especially in clinical trials for leukemia and colorectal tumors, mostly discontinued before the late 1980s)[6]. It is known for its **extreme toxicity** by ingestion, inhalation, or parenteral administration, with noted effects including muscle weakness, nausea, vomiting, fever, and teratogenicity[2][6].

Other names
anguidineDASanguidin4,15-diacetoxyscirpenoldiacetoxysciroenoldiacetoxyscirpenol solution12,13-epoxytrichothec-9-ene-3,4,15-triol-4,15-diacetate3,5-diacetoxyscirpenoltrichothec-9-ene-3alpha,4beta,15-triol, 12,13-epoxy-4,15-diacetatescirpenetriol 4,15-diacetate
02

Targets

28S rRNA (28S ribosomal RNA)

Beyond the preview

Go deeper on diacetoxyscirpenol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diacetoxyscirpenol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call